{
    "clinical_study": {
        "@rank": "106067", 
        "acronym": "CAPE", 
        "arm_group": [
            {
                "arm_group_label": "Adalimumab (Humira) Treatment", 
                "description": "Pediatric patients who are prescribed and treated with adalimumab"
            }, 
            {
                "arm_group_label": "Immunosuppressant Therapy", 
                "description": "Pediatric patients who are being prescribed and treated with immunosuppressant therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in\n      pediatric patients with moderately to severely active CD who are treated as recommended in\n      the product label."
        }, 
        "brief_title": "A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)", 
        "completion_date": {
            "#text": "April 2030", 
            "@type": "Anticipated"
        }, 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. For a patient enrolling into the HUMIRA treatment group; A pediatric patient between\n             the ages of 6 and 17 years inclusive at the time of enrollment, diagnosed with\n             moderately to severely active CD who has been prescribed Humira therapy according to\n             the local approved Humira product label.\n\n          2. For a patient enrolling into the immunosuppressant therapy treatment group; A\n             pediatric patient between the ages of 6 and 17 years inclusive at the time of\n             enrollment, diagnosed with moderately to severely active CD who has been prescribed\n             azathioprine, 6-mercaptopurine or methotrexate.\n\n          3. Parent or guardian; or patient (if 18 years of age or older at enrollment and rolling\n             over from an AbbVie-sponsored investigational Pediatric CD investigation trial) has\n             voluntarily signed and dated an Authorization for Use/Disclosure of Data\n             (AUDD)/informed consent form (ICF) after the nature of the registry has been\n             explained and the patient, patient's parent or legal guardian has had the opportunity\n             to ask questions.\n\n        Exclusion Criteria:\n\n          1. Patients should not be enrolled into the HUMIRA treatment group if they cannot be\n             treated in accordance with the local Humira product label.\n\n          2. Patients should not be enrolled into the registry if they are currently being treated\n             with any investigational agents or are receiving any investigational procedures.\n\n          3. Patients should not be enrolled into the immunosuppressant therapy treatment group if\n             they require ongoing treatment with approved biologic agents including HUMIRA."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "6 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Pediatric patients with moderately to severly active Crohn's Disease (CD) who have\n        prescribed HUMIRA according to the local label and pediatric patients being prescribed and\n        treated with IMM (azathioprine, 6-mercaptopurine, or methotrexate). Patients being\n        prescribed and treated with immunosuppressant therapy with no concurrent biologic use will\n        be enrolled as a reference group."
            }
        }, 
        "enrollment": {
            "#text": "1300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02130362", 
            "org_study_id": "P11-292"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunosuppressive Agents", 
                "Adalimumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Crohn's", 
            "Crohn's Disease", 
            "Registry", 
            "Gastrointestinal Diseases", 
            "Inflammatory Bowel Diseases", 
            "Adalimumab"
        ], 
        "lastchanged_date": "May 1, 2014", 
        "link": {
            "url": "http://www.rxabbvie.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Varna", 
                        "country": "Bulgaria", 
                        "zip": "9010"
                    }, 
                    "name": "Site Reference ID/Investigator# 127435"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127435", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "zip": "B3K 6R8"
                    }, 
                    "name": "Site Reference ID/Investigator# 127912"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127912", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "zip": "K1H 8L1"
                    }, 
                    "name": "Site Reference ID/Investigator# 127911"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127911", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "zip": "M5G1X8"
                    }, 
                    "name": "Site Reference ID/Investigator# 127910"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127910", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic", 
                        "zip": "77900"
                    }, 
                    "name": "Site Reference ID/Investigator# 127437"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127437", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ostrava-Poruba", 
                        "country": "Czech Republic", 
                        "zip": "708 52"
                    }, 
                    "name": "Site Reference ID/Investigator# 127913"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127913", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic", 
                        "zip": "150 06"
                    }, 
                    "name": "Site Reference ID/Investigator# 126122"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 126122", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague 10", 
                        "country": "Czech Republic", 
                        "zip": "100 34"
                    }, 
                    "name": "Site Reference ID/Investigator# 127697"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127697", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tallinn", 
                        "country": "Estonia", 
                        "zip": "Ravi 27"
                    }, 
                    "name": "Site Reference ID/Investigator# 126974"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 126974", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aachen", 
                        "country": "Germany", 
                        "zip": "52074"
                    }, 
                    "name": "Site Reference ID/Investigator# 126591"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 126591", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "1307"
                    }, 
                    "name": "Site Reference ID/Investigator# 127696"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127696", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Forchheim", 
                        "country": "Germany", 
                        "zip": "91301"
                    }, 
                    "name": "Site Reference ID/Investigator# 127975"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127975", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "80337"
                    }, 
                    "name": "Site Reference ID/Investigator# 126035"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 126035", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland", 
                        "zip": "Dublin 12"
                    }, 
                    "name": "Site Reference ID/Investigator# 127438"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127438", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "zip": "G3 8SJ"
                    }, 
                    "name": "Site Reference ID/Investigator# 127436"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127436", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SW10 9NH"
                    }, 
                    "name": "Site Reference ID/Investigator# 126972"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 126972", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Canada", 
                "Czech Republic", 
                "Estonia", 
                "Germany", 
                "Ireland", 
                "United Kingdom"
            ]
        }, 
        "number_of_groups": "2", 
        "official_title": "A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE", 
        "overall_contact": {
            "email": "julie.gavigan@abbvie.com", 
            "last_name": "Julie  Gavigan, BS", 
            "phone": "8479375472"
        }, 
        "overall_contact_backup": {
            "email": "laura.swingle@abbvie.com", 
            "last_name": "Laura  Swingle, BS", 
            "phone": "8474149409"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Andreas  Lazar, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Greece: National Organization of Medicines", 
                "Spain: Ministry of Health", 
                "Portugal: Health Ethic Committee", 
                "Czech Republic: Ethics Committee", 
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "Sweden: Regional Ethical Review Board", 
                "Denmark: Danish Dataprotection Agency", 
                "Italy: Ethics Committee", 
                "Bulgaria: Ethics committee", 
                "Romania: Ethics Committee", 
                "Australia: Human Research Ethics Committee", 
                "Germany: Paul-Ehrlich-Institut", 
                "Ireland: Research Ethics Committee", 
                "Norway: Norwegian Medicines Agency", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Israel: Ethics Commission", 
                "United Kingdom: Research Ethics Committee", 
                "France: French Data Protection Authority", 
                "Bosnia: Federal Ministry of Health", 
                "United States: Food and Drug Administration", 
                "Australia: National Health and Medical Research Council", 
                "Spain: Ethics Committee", 
                "France: Conseil National de l'Ordre des M\u00e9decins", 
                "Croatia: Agency for Medicinal Product and Medical Devices", 
                "Estonia: Research Ethics Committee", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Denmark: Danish Health and Medicines Authority", 
                "Slovenia: Ethics Committee", 
                "Bulgaria: Ministry of Health", 
                "Greece: Ethics Committee"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2030", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects with Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "measure": "Percentage of subjects with SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "measure": "Number of subjects with Adverse Events of Special Interest (AESI) of infections, malignancies, and pregnancies", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "measure": "Percentage of subjects with AESI of infections, malignancies, and pregnancies", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "description": "Number of subjects with AESIs other than infections and malignancies", 
                "measure": "Number of subjects with other AESI", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Percentages of subjects with AESIs other than infections and malignancies", 
                "measure": "Percentage of subjects with other AESI", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Number of treatment-emergent SAEs per 100 patient years (PYs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "measure": "Number of treatment-emergent AESI per 100 PYs of infections and malignancies", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "measure": "Number of treatment-emergent other AESI per 100 PYs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02130362"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patient completed questionnaires", 
                "measure": "Short Pediatric Crohn's Disease Activity Index (sh-PCDAI)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Completed by the physician", 
                "measure": "Physician's Global Assessment of Disease Activity (PGA)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Completed by patients ages 10 through 17 years old", 
                "measure": "IMPACT III", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Completed by the patients who are 18 years of age or older", 
                "measure": "Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Completed by caregiver up to the age of 17 years and completed by the patients of age 18 years or above.", 
                "measure": "Work Productivity and Activity Impairment (WPAI) questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}